Medical Service, VA Connecticut Healthcare System, West Haven, CT 06516, USA.
Blood Purif. 2010;29(3):264-7. doi: 10.1159/000274460.
A direct relationship between dialysate-to-plasma sodium gradient, blood pressure and interdialytic weight gain exists in hemodialysis (HD) patients. The aim of this study was to delineate the long-term variability of serum sodium in HD patients.
We performed a retrospective cohort analysis of serum sodium and other analytes routinely evaluated in 100 stable chronic HD patients observed for 12 months.
Individual levels across the cohort varied from 122 to 145 m M , but 12-month intraindividual coefficients of variation for sodium were low (pre-HD = 1.6%; post-HD = 1.8%) with overall variability similar to that related to laboratory assay variability especially when compared with other analytes (3.1-30.8%). Pre-HD serum sodium had a trend toward hyponatremia (mean 136 +/- 0.8 m M ).
Serum sodium is stable over time in HD patients. Pre-HD serum sodium may be used as a parameter for individualizing dialysate sodium prescription.
在血液透析(HD)患者中,透析液与血浆钠梯度、血压和透析间期体重增加之间存在直接关系。本研究旨在描述 HD 患者血清钠的长期变异性。
我们对 100 例稳定慢性 HD 患者的血清钠和其他常规评估的分析物进行了回顾性队列分析,这些患者观察了 12 个月。
整个队列的个体水平从 122 到 145mM 不等,但钠的 12 个月个体内变异系数较低(HD 前=1.6%;HD 后=1.8%),总体变异性与实验室检测变异性相似,尤其是与其他分析物(3.1-30.8%)相比。HD 前血清钠呈低钠血症趋势(平均 136 +/- 0.8mM)。
在 HD 患者中,血清钠随时间稳定。HD 前血清钠可作为个体化透析液钠处方的参数。